Barclays
COGT icon

Barclays’s Cogent Biosciences COGT Stock Holding History

Barclays’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Sell
31,261
-290,345
-90% -$10.7M ﹤0.01% 2639
2025
Q4 		$11.4M Sell
321,606
-38,224
-11% -$1.07M ﹤0.01% 1586
2025
Q3 		$5.17M Buy
359,830
+39,265
+12% +$465K ﹤0.01% 2169
2025
Q2 		$2.3M Buy
320,565
+145,647
+83% +$807K ﹤0.01% 2740
2025
Q1 		$1.05M Sell
174,918
-18,150
-9% -$142K ﹤0.01% 3079
2024
Q4 		$1.51M Buy
193,068
+17,384
+10% +$173K ﹤0.01% 3105
2024
Q3 		$1.9M Buy
175,684
+97,541
+125% +$950K ﹤0.01% 2895
2024
Q2 		$659K Sell
78,143
-29,510
-27% -$224K ﹤0.01% 2863
2024
Q1 		$723K Sell
107,653
-121,552
-53% -$751K ﹤0.01% 3348
2023
Q4 		$1.35M Buy
229,205
+118,293
+107% +$906K ﹤0.01% 3218
2023
Q3 		$1.08M Sell
110,912
-1,481
-1% -$17.6K ﹤0.01% 2280
2023
Q2 		$1.33M Buy
112,393
+4,595
+4% +$52.7K ﹤0.01% 2130
2023
Q1 		$1.16M Sell
107,798
-71,694
-40% -$917K ﹤0.01% 2621
2022
Q4 		$2.07M Buy
179,492
+31,236
+21% +$387K ﹤0.01% 2238
2022
Q3 		$2.21M Buy
148,256
+145,473
+5,227% +$1.99M ﹤0.01% 1683
2022
Q2 		$25K Sell
2,783
-31,359
-92% -$214K ﹤0.01% 4306
2022
Q1 		$257K Buy
+34,142
New +$238K ﹤0.01% 3272
2020
Q3 		– Sell
-1,869
Closed -$3K – 5259
2020
Q2 		$3K Buy
+1,869
New +$3.47K ﹤0.01% 5419
2020
Q1 		– Sell
-6,338
Closed -$18K – 6172
2019
Q4 		$18K Sell
6,338
-261
-4% -$1.06K ﹤0.01% 6000
2019
Q3 		$38K Sell
6,599
-7,958
-55% -$64.7K ﹤0.01% 6013
2019
Q2 		$152K Buy
14,557
+13,120
+913% +$175K ﹤0.01% 5347
2019
Q1 		$25K Buy
+1,437
New +$24.6K ﹤0.01% 6260
2018
Q4 		– Sell
-1,587
Closed -$65K – 6982
2018
Q3 		$65K Buy
1,587
+1,522
+2,342% +$85.8K ﹤0.01% 5893
2018
Q2 		$4K Buy
+65
New +$3.12K ﹤0.01% 6732

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Barclays's COGT Position: Q1 2026 in Review

Barclays reduced its Cogent Biosciences (COGT) stake by 90% in Q1 2026, selling an estimated $10.7M and leaving 31,261 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

Barclays first reported a position in COGT in Q2 2018 and has held it in 24 quarters since. The position peaked at $11.4M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Barclays held 31,261 shares of Cogent Biosciences worth $1.2M as of Q1 2026.
  • Barclays sold 290,345 Cogent Biosciences shares in Q1 2026, an estimated $10.7M.
  • Cogent Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2639 holding.
  • Barclays first reported a position in Cogent Biosciences in Q2 2018 and has held it in 24 quarters since.
  • Barclays's Cogent Biosciences position peaked at $11.4M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.